Tandem Diabetes Care (TNDM) Net Equity Issued and Repurchased (2013 - 2024)

Tandem Diabetes Care (TNDM) has 12 years of Net Equity Issued and Repurchased data on file, last reported at $2.3 million in Q4 2024.

• Quarterly Net Equity Issued and Repurchased fell 12.04% year-over-year to $2.3 million in Q4 2024, while the trailing twelve-month figure through Dec 2024 was -$6.7 million (down 260.85% YoY) and the FY2024 annual result came in at -$6.7 million, down 260.85% from the prior year.
• Net Equity Issued and Repurchased grew to $2.3 million in Q4 2024, from -$4.5 million in the prior quarter.
• In the past five years, Net Equity Issued and Repurchased ranged from a high of $29.0 million in Q3 2020 to a low of -$4.5 million in Q3 2024.
• A 5-year average of $6.7 million and a median of $3.7 million in 2022 frame the typical range for Net Equity Issued and Repurchased.
• Annual changes were most pronounced in 2020 — Net Equity Issued and Repurchased surged 504.53% — and 2023, when it tumbled 398.64%.
• Tracing TNDM's Net Equity Issued and Repurchased over 5 years: stood at $9.2 million in 2020, then soared by 72.89% to $15.9 million in 2021, then tumbled by 61.6% to $6.1 million in 2022, then sank by 57.1% to $2.6 million in 2023, then retreated by 12.04% to $2.3 million in 2024.
• The last three Net Equity Issued and Repurchased figures came in at $2.3 million (Q4 2024), -$4.5 million (Q3 2024), and -$3.0 million (Q2 2024), per Business Quant data.